The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Advanced Thromboembolism Prophylaxis

Risk-stratified pharmacological and mechanical strategies for VTE prevention in surgical and medical patients.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Kardiyoloji department. Book Appointment →

What is Advanced Thromboembolism Prophylaxis?

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading preventable cause of in-hospital mortality. Advanced prophylaxis stratifies patients using validated tools — Caprini score for surgical patients, Padua and IMPROVE for medical patients, Khorana for cancer outpatients on chemotherapy — to determine appropriate intensity and duration of prophylaxis.

Pharmacological options include low-molecular-weight heparin (enoxaparin, dalteparin), fondaparinux, unfractionated heparin (5000 IU q8-12h), and direct oral anticoagulants (rivaroxaban, apixaban, betrixaban) for selected medical and orthopedic patients. Extended prophylaxis (28-35 days) is indicated after major orthopedic surgery (total hip and knee arthroplasty) and major abdominopelvic cancer surgery. Aspirin alone is acceptable in lower-risk arthroplasty per ASRA.

Mechanical prophylaxis (intermittent pneumatic compression, graduated compression stockings) is used when bleeding risk precludes pharmacotherapy, in combination with pharmacological agents in high-risk surgery, or until pharmacotherapy can begin. Inferior vena cava filters are reserved for patients with acute VTE and absolute contraindication to anticoagulation. Cancer-associated thrombosis prefers LMWH or apixaban/rivaroxaban (not GI/GU malignancy). Pediatric, pregnancy, renal failure, and obesity require specialized dosing protocols.

Symptoms

Patient at risk for VTE (surgery, immobility, cancer)
Major orthopedic surgery (hip/knee arthroplasty)
Active malignancy on chemotherapy
Acute medical illness with reduced mobility
Pregnancy with thrombophilia history
Trauma or critical illness
Prior unprovoked VTE

Risk Factors

Active cancer or chemotherapy
Major surgery (especially orthopedic, oncologic)
Immobilization > 72 hours
Prior VTE
Thrombophilia (factor V Leiden, antiphospholipid)
Obesity (BMI > 30)
Estrogen therapy or pregnancy

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Hospital admission with risk factors
  • Pre-operative VTE risk assessment
  • Cancer diagnosis on chemotherapy
  • Pregnancy with prior VTE
  • Symptoms of DVT or PE despite prophylaxis
  • Bleeding event during anticoagulation

Treatment Methods

01
Risk stratification with Caprini, Padua, IMPROVE
02
LMWH (enoxaparin 40 mg daily) standard prophylaxis
03
DOAC (rivaroxaban, apixaban) for selected indications
04
Extended prophylaxis 28-35 days post-arthroplasty/cancer
05
Mechanical prophylaxis (IPC, GCS) when bleeding risk
06
IVC filter only if absolute anticoagulation contraindication
07
Patient education on early ambulation

Which Department to Visit?

You can visit our Kardiyoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Kardiyoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.